期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 168, 期 3, 页码 395-404出版社
WILEY
DOI: 10.1111/bjh.13142
关键词
acute lymphoblastic leukaemia; minimal residual disease; bone marrow transplantation; IKZF1; childhood leukaemia
类别
资金
- NHMRC Australia
- Cancer Council NSW
- Leukaemia Foundation
Minimal residual disease (MRD) during early chemotherapy is a powerful predictor of relapse in acute lymphoblastic leukaemia (ALL) and is used in children to determine eligibility for allogeneic haematopoietic stem cell transplantation (HSCT) in first (CR1) or later complete remission (CR2/CR3). Variables affecting HSCT outcome were analysed in 81 children from the ANZCHOG ALL8 trial. The major cause of treatment failure was relapse, with a cumulative incidence of relapse at 5years (CIR) of 32% and treatment-related mortality of 8%. Leukaemia-free survival (LFS) and overall survival (OS) were similar for HSCT in CR1 (LFS 62%, OS 83%, n=41) or CR2/CR3 (LFS 60%, OS 72%, n=40). Patients achieving bone marrow MRD negativity pre-HSCT had better outcomes (LFS 83%, OS 92%) than those with persistent MRD pre-HSCT (LFS 41%, OS 64%, P<00001) or post-HSCT (LFS 35%, OS 55%, P<00001). Patients with B-other ALL had more relapses (CIR 50%, LFS 41%) than T-ALL and the main precursor-B subtypes including BCR-ABL1, KMT2A (MLL), ETV6-RUNX1 (TEL-AML1) and hyperdiploidy >50. A Cox multivariate regression model for LFS retained both B-other ALL subtype (hazard ratio 41, P=00062) and MRD persistence post-HSCT (hazard ratio 39, P=00070) as independent adverse prognostic variables. Persistent MRD could be used to direct post-HSCT therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据